Peer-reviewed veterinary case report
Survival and blood markers in dogs treated for bone cancer
By Gieger, Tracy L et al.·Published in Canadian journal of veterinary research = Revue canadienne de recherche veterinaire·2017·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The impact of carboplatin and toceranib phosphate on serum vascular endothelial growth factor (VEGF) and metalloproteinase-9 (MMP-9) levels and survival in canine osteosarcoma.
- Species:
- dog
Plain-English summary
Ten dogs with osteosarcoma (a type of bone cancer) underwent amputation followed by chemotherapy with carboplatin and toceranib phosphate. Throughout the treatment, the dogs were monitored for side effects, and none were removed from the study due to toxicity. Unfortunately, most dogs experienced local recurrence or metastasis and passed away, with a median survival time of about 253 days. While the treatment was well-tolerated, it did not improve survival times compared to traditional amputation and chemotherapy alone.
People also search for: dog osteosarcoma treatment · carboplatin for dogs · toceranib phosphate side effects
Abstract
In this pilot study, 10 dogs with osteosarcoma (OSA) were treated with amputation and subsequent carboplatin chemotherapy (300 mg/mIV q3wk × 4 doses) followed by toceranib phosphate (2.75 mg/kg PO q48h starting at day 14 post carboplatin). Monthly clinical monitoring and serum measurements of vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) were acquired. No dogs were removed from the study due to toxicity. Levels of VEGF and MMP-9 did not change over time. Seven dogs died related to local recurrence and/or pulmonary or bone metastasis and the remainder died of other causes. Median OSA-free survival was 238 d with 34% 1-year progression-free survival. Median overall survival was 253 d with 30% alive at 1.5 y and 10% alive at 2 y. Although this regimen was well-tolerated, survival times did not exceed previously published data from dogs treated with amputation plus chemotherapy alone.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28725110/